Glucose News and Research

RSS

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

The National Institutes of Health has awarded $10.24 million to Fred Hutchinson Cancer Research Center to lead a five-year study that aims to understand and prevent breast cancer disparities in Hispanic women.

4 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

MicroCHIPS, Inc., a developer of intelligent implant systems, today announced that it has received a 2010 Edison Best New Product Award for its Illume product. The product was awarded Gold in the Science and Medical Category, recognizing the benefit that it will bring to millions of people with diabetes who must manage their blood sugar intensively to stay healthy.

30 Apr 2010

Improved management practices can reduce annual costs from diabetes-related complications

Milliman Inc., a premier global consulting and actuarial firm, today released an analysis detailing the economic burden of type 2 diabetes on major healthcare payers and quantifying the savings that could result from better patient management practices.

29 Apr 2010

Many Americans aren't taking necessary steps to protect against diabetes: Study

Diabetes affects more than 23 million people in the United States today and another 54 million people have pre-diabetes, according to the Centers for Disease Control and Prevention. However, while nearly 60 percent of Americans are concerned about developing diabetes, many aren't taking the necessary steps to protect their health, according to a recent study by the International Diabetes Center and Abbott.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

PositiveID, Receptors announce milestone in development of in vivo glucose-sensing RFID microchip

PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that the companies have achieved a milestone in the development of their in vivo glucose-sensing RFID microchip to detect glucose levels in the body. The companies have completed the synthesis of a new chemical building block that will serve as the anchor of their next generation of Combinatorial Artificial Receptor (CARA™) surfaces for the sensing system component of the implantable glucose sensor.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

The Frost Group agrees to make investment in ChromaDex

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, announced today The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex.

26 Apr 2010

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Bayer Diabetes Care today announced the introduction of the DIDGET™ blood glucose monitoring system in the United States. The DIDGET meter is unique because it is the only blood glucose meter that connects directly to Nintendo DS™ and DS Lite gaming systems to help kids manage a lifelong disease by rewarding them for building consistent testing habits and meeting personalized blood glucose target ranges. Bayer's DIDGET meter is now available for purchase in the U.S. through CVS.com, Drugstore.com and Walgreens.com.

26 Apr 2010

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Scientists at the University of Michigan Health System are teasing out clues to the effect of grapes in reducing risk factors related to cardiovascular disease and metabolic syndrome. The effect is thought to be due to phytochemicals -- naturally occurring antioxidants - that grapes contain.

26 Apr 2010

Chokeberry extract reduces weight gain in insulin-resistant animals

Chokeberry bushes have for centuries been residents of eastern deciduous forests where their bright red and dark purple fruits continue to be favorite snacks of local bird species. Native Americans have also traditionally eaten dried chokeberries and prepared teas from parts of the plant, and several domesticated varieties now grace contemporary lawns and gardens from coast to coast.

26 Apr 2010

Highlights from AACE 19th Annual Meeting and Clinical Congress

today's highlights from the AACE Annual Meeting & Clinical Congress in Boston

24 Apr 2010

Study finds AFREZZA comparable to standard of care insulin therapy

Pulmonary function test results (PFTs) in patients treated with AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, at follow-up measurements were similar to PFT results observed in patients receiving standard antidiabetic therapy, according to data presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #267).

24 Apr 2010

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

Diabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #283).

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Research associates diabetes with atrial fibrillation

As the U.S. population keeps aging and gaining weight, diabetes is becoming increasingly common. Some research has associated diabetes with the most common kind of chronically irregular heartbeat, called atrial fibrillation, which can raise the risk for stroke and death. But results of past studies of diabetes and atrial fibrillation have conflicted.

23 Apr 2010

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today announced it has completed a $39.6 million Series A financing led by SV Life Sciences, Clarus Ventures, and MedImmune Ventures. Also participating in the round is Advanced Technology Ventures.

21 Apr 2010

New sensor wristband monitors various body functions

A small blood lab that fits into the pocket of a jacket can quickly analyze the risk of blood clots in legs prior to a long distance flight; a sensor wristband for measuring electric smog can warn pacemaker patients of life-threatening exposure: "Smart plastics" can turn such tools into reality.

21 Apr 2010

Glucose News and Research

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Majority of patients who appear healthy may be at risk for cardiovascular disease

MicroCHIPS receives 2010 Edison Best New Product Award for Illume System

Improved management practices can reduce annual costs from diabetes-related complications

Many Americans aren't taking necessary steps to protect against diabetes: Study

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

PositiveID, Receptors announce milestone in development of in vivo glucose-sensing RFID microchip

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

The Frost Group agrees to make investment in ChromaDex

Bayer Diabetes Care launches DIDGET blood glucose monitoring system in the US

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Chokeberry extract reduces weight gain in insulin-resistant animals

Highlights from AACE 19th Annual Meeting and Clinical Congress

Study finds AFREZZA comparable to standard of care insulin therapy

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Research associates diabetes with atrial fibrillation

Catabasis Pharmaceuticals to advance program targeting type 2 diabetes with $39.6 million Series A financing

New sensor wristband monitors various body functions

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News